Syndrome Patterns for Chronic Atrophic Gastritis Malignant Transformation

Sponsor
Beijing University of Chinese Medicine (Other)
Overall Status
Recruiting
CT.gov ID
NCT03314038
Collaborator
The University of Science and Technology of China (Other), China Academy of Chinese Medical Sciences (Other), Harvard Medical School (HMS and HSDM) (Other)
2,000
1
96
20.8

Study Details

Study Description

Brief Summary

Chronic atrophic gastritis (CAG) is acknowledged as the precancerous stage of gastric cancer (GC). The present study aims to explore Traditional Chinese Medicine (TCM) syndrome features in different stages of CAG malignant transformation respectively. The proposed study is a cross-sectional study based participant survey conducted in 4 hospitals in Beijing, China. After obtaining informed consent, a total of 2000 study patients will be recruited on-site in hospitals.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    CAG is acknowledged as the precancerous stage GC. Active treatment of CAG is vital in arresting malignant transformation. Traditional Chinese medicine (TCM) has been widely used in treating CAG and preventing GC in China. To date, few study has been conducted to assess the syndrome features of different stages of CAG malignant transformation combining TCM indicators.

    The present study aims to explore TCM syndrome features in different stages of CAG malignant transformation. The proposed study is a registry study based participant survey conducted in 4 hospitals in Beijing, China. After obtaining informed consent, a total of 2000 eligible study patients will berecruited on-site in hospitals.

    Comparative analysis of prevalence of presenting TCM features is conducted using frequency analysis and chi-squared tests, and expressed with composition ratios. Exploratory factor analysis,correspondence analysis, association rule analysis, hierarchical clustering analysis, and complex system entropy clustering analysis will be performed respectively for validating features of syndrome in different stages of CAG malignant transformation.

    Previous reports on TCM syndrome features for CAG exist, but no studies have been undertaken base on large-sampled study design and detailed analysis in different stages of CAG malignant transformation respectively.

    The outcome of our study has the potential to clerify core TCM pathogenesis of CAG, facilitate early intervention, and promote optimization of treatment strategies of CAG malignant transformation by TCM.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    2000 participants
    Observational Model:
    Other
    Time Perspective:
    Cross-Sectional
    Official Title:
    Validating Features of Traditional Chinese Syndrome Patterns for Chronic Atrophic Gastritis Malignant Transformation: A Cross-sectional Study
    Actual Study Start Date :
    Jan 1, 2014
    Anticipated Primary Completion Date :
    Dec 31, 2021
    Anticipated Study Completion Date :
    Dec 31, 2021

    Outcome Measures

    Primary Outcome Measures

    1. TCM syndrome [one time at involvement (1 day)]

      According to the symptoms and physical signs of patients to determine the syndrome

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 75 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • (1) 18-75 years of age; (2) Meeting diagnostic criteria of CAG after upper gastrointestinal endoscopy; (3) Willing to cooperate with data, tissue sample, and blood sample collection during recruitment; (4) Willing to respond truthfully and timely to researcher queries after recruitment, able to cooperate with data, tissue sample and blood sample collection during follow-ups; (5) Willing to sign informed consent.
    Exclusion Criteria:
    • (1) Meeting past history of previous stomach surgery; (2) Unable to participate in data, tissue sample or blood sample collection for any reason.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Beijing University of Chinese Medicine Beijing Beijing China 100029

    Sponsors and Collaborators

    • Beijing University of Chinese Medicine
    • The University of Science and Technology of China
    • China Academy of Chinese Medical Sciences
    • Harvard Medical School (HMS and HSDM)

    Investigators

    • Principal Investigator: Xia Ding, MD, Beijing University of Chinese Medicine

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Dr. Xia Ding, Professor, Beijing University of Chinese Medicine
    ClinicalTrials.gov Identifier:
    NCT03314038
    Other Study ID Numbers:
    • 81630080-CAG-CS
    First Posted:
    Oct 19, 2017
    Last Update Posted:
    Feb 1, 2021
    Last Verified:
    Jan 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Dr. Xia Ding, Professor, Beijing University of Chinese Medicine
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 1, 2021